A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2017 |
| Start Date: | March 9, 2018 |
| End Date: | September 29, 2019 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email: |
A Phase Ib/II Safety Trial of Nivolumab in Combination With Ipilimumab Administered in Participants With Chemotherapy-naive Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (CheckMate 955: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 955)
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent
Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent
Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- 1) Stage IV or recurrent non-Small cell lung cancer
- 2) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- 3) Prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if
completed at least 6 months prior to randomization
Exclusion Criteria:
- 1) Known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma
syndrome(ALK) translocations that are sensitive to targeted inhibitor therapy
- 2) Active, known or suspected autoimmune disease or HIV infection
- 3) Prior treatment with any drug that targets T cell co-stimulation pathways (such as
checkpoint inhibitors)
- 4) Untreated Central Nervous System metastases
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials